Reviewing Research Efforts Seeking to Raise the Bar in Myelofibrosis

Joseph M. Scandura, MD, PhD, discusses the phase 2 SENTRY-2 study evaluating single-agent selinexor in JAK inhibitor–naive myelofibrosis.

Joseph M. Scandura, MD, PhD, discusses the importance of research with single-agent selinexor in JAK inhibitor–naive myelofibrosis.

John Mascarenhas, MD, discusses the use of selinexor with ruxolitinib in JAK inhibitor–naive myelofibrosis, highlighting the phase 2 XPORT-MF-044 trial

Selinexor is under investigation as monotherapy and in combination with the JAK inhibitor ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

Srinivas K. Tantravahi, MBBS, MRCP, discusses the preliminary efficacy of selinexor in combination with ruxolitinib in patients with JAK inhibitor–naive myelofibrosis, as seen in the phase 1 XPORT-MF-034 trial.

John Mascarenhas, MD, discusses the potential advantages of utilizing selinexor with ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

Aaron Gerds, MD, discusses the importance of evaluating the efficacy and safety of selinexor in patients with JAK inhibitor–naive myelofibrosis, as assessed in the phase 1/3 XPORT-MF-034 trial.

The oral XPO1 inhibitor selinexor in combination with ruxolitinib was associated with a tolerable and manageable adverse effect profile and elicited signals of clinical efficacy in patients with JAK inhibitor–naive myelofibrosis.